In Vitro Evaluation of the Effects of Zearalenone and α-Zearalenol on MCF-7 and MDA-MB-468 Cell Lines of Human Breast Cancer

Document Type : Original Article

Authors

1 Department of Biology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, IR Iran

2 Department of Biology, Faculty of Sciences, Razi University of Kermanshah, Kermanshah, IR Iran

10.30483/rijm.2015.118392

Abstract

Background: In the field of human breast cancer, the most recent researches referred to the influence of endogenous estrogen or exposure to environmental estrogen, as risk factors. Zearalenone (ZEN) as a mycotoxin and its derivative α- zearalenol (α-ZOL) are known nonsteroidal estrogenic compounds with potential endocrine disrupting properties. Objectives: The present study was designed to investigate the effects of ZEN and α-ZOL on human breast cancer cell lines MCF-7 and MDAMB-468. Materials and Methods: Cell lines were treated by low and high doses of ZEN and α-ZOL (0, 1, 30, 62, 125, 250 and 500 ng/ml and 1, 2, 4, 8, 15, 30, 62 and 125 µg/ml) for 24 and 48 hours. Then MTT colorimetric assay was used to evaluate the cytotoxicity effect of ZEN and α-ZOL. Furthermore, morphological changes of treated and untreated cell lines were studied under an inverted microscope. Results: The results obtained from the present study demonstrated that both ZEN and α-ZOL enhance the cell viability of MCF-7 especially at low doses (1 - 500 ng/ml) and at a high dose of 125µg/ml after 24 and 48 hours. However, this effect for α-ZOL was somewhat greater than that for ZEN. On the other hand, these estrogenic compounds did not have any effect on the cell viability of MDA-MB-468. No morphological change was observed in treated cells. Conclusions: These results show that ZEN and α-ZOL enhance the rate of cell division in ER positive cells and therefore, exposure to this mycotoxin may increase the risk of breast cancer.

Keywords


  1. 1.Sushma K, Praveen K, Poonam R. Medicinal plants of Asian origin having anticancer potential. A J B P S. 2012;2:1–7.

    1. WHO. Global status report on non-communicable diseases 2010. Geneva: World Health Organization; 2011.
    2. Datta K, Choudhuri M, Guha S, Biswas J. Breast cancer scenario in a regional cancer centre in Eastern India over eight years- -still a major public health problem. Asian Pac J Cancer Prev. 2012;13(3):809–13. [PubMed: 22631653]
    3. Ministry of Health and Medical Education CFDMCD. National Registration Cancer Cases Reported in 2010. Iran; Center for Disease Management. 2013.
    4. Hosseinzadeh M, Eivazi Ziaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A, et al. Risk factors for breast cancer in Iranian women: a hospital-based case-control study in tabriz, iran. J Breast Cancer. 2014;17(3):236–43. doi: 10.4048/jbc.2014.17.3.236. [PubMed: 25320621]
    5. ACS (American Cancer Society). Breast cancer facts and figures. 2014. Available from: http:// ww.cancer.org.
    6. Abdel-Rahman WM, Moustafa Yasser M, Ahmed BO, Mostafa RM. Endocrine Disruptors and Breast Cancer Risk. Asian Pac J Cancer Prev. 2012;13:5937–46.
    7. Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365–77. doi: 10.1007/s10549-011-1818-2. [PubMed: 22037780]
    8. Bowlin SJ, Leske MC, Varma A, Nasca P, Weinstein A, Caplan L. Breast cancer risk and alcohol consumption: results from a large case-control study. Int J Epidemiol. 1997;26(5):915–23. [PubMed: 9363510]
    9. Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, et al. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect. 1996;104 Suppl 4:715–40. [PubMed: 8880000] 11. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15(1):17–35. [PubMed: 8405201]
    10. Darbre PD, Aljarrah A, Miller WR, Coldham NG, Sauer MJ, Pope GS. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004;24(1):5–13. doi: 10.1002/jat.958. [PubMed: 14745841]
    11. Hertz R. The estrogen problem-retrospect and prospect In: Estrogens in the Environment II-Inflences on Development. New York: Elsevier; 1985. pp. 1–11.
    12. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr. 1997;17:353–81. doi: 10.1146/annurev.nutr.17.1.353. [PubMed: 9240932]
    13. Fink-Gremmels J, Malekinejad H. Clinical effects and biochemical mechanisms associated with exposure to the mycoestrogen zearalenone. Anim Feed Sci Technol. 2007;137:326–41.
    14. Zatecka E, Ded L, Elzeinova F, Kubatova A, Dorosh A, Margaryan H, et al. Effect of zearalenone on reproductive parameters and expression of selected testicular genes in mice. Reprod Toxicol. 2014;45:20–30. doi: 10.1016/j.reprotox.2014.01.003. [PubMed: 24412631]
    15. Minervini F, Dell'Aquila ME. Zearalenone and reproductive function in farm animals. Int J Mol Sci. 2008;9(12):2570–84. doi: 10.3390/ijms9122570. [PubMed: 19330093]
    16. Olsen M, Pettersson H, Sandholm K, Visconti A, Kiessling KH. Metabolism of zearalenone by sow intestinal mucosa in vitro. Food Chem Toxicol. 1987;25(9):681–3. [PubMed: 2958396]
    17. Biehl ML, Prelusky DB, Koritz GD, Hartin KE, Buck WB, Trenholm HL. Biliary excretion and enterohepatic cycling of zearalenone in immature pigs. Toxicol Appl Pharmacol. 1993;121(1):152–9. doi: 10.1006/taap.1993.1140. [PubMed: 8337696]
    18. Karami-Tehrani F, Salami S. Cell Kinetic Study of Tamoxifen Treated MCF-7 and MDA-MB 468 Breast Cancer Cell Line. Iran Biomed J. 2003;7:51–6.
    19. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009;69(8):3405–14. doi: 10.1158/0008-5472.CAN-08-3628. [PubMed: 19351845]
    20. Wang L, Di LJ. BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact? Int J Biol Sci. 2014;10(5):566–75. doi: 10.7150/ijbs.8579. [PubMed: 24910535]
    21. Recchia AG, Vivacqua A, Gabriele S, Carpino A, Fasanella G, Rago V, et al. Xenoestrogens and the induction of proliferative Parandin R et al. Razavi Int J Med. 2015;3(4):e30231 17 effects in breast cancer cells via direct activation of oestrogen receptor alpha. Food Addit Contam. 2004;21(2):134–44. doi: 10.1080/02652030310001641177. [PubMed: 14754635]
    22. Dairkee SH, Luciani-Torres MG, Moore DH, Goodson WH. Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis. 2013;34(3):703–12. doi: 10.1093/carcin/bgs379. [PubMed: 23222814]
    23. Kaabinejadian S, Fouladdel S, Ramezani M, Azizi E. Molecular analysis of Bcl-2 and cyclin D1 expression in differentially expressing estrogen receptor breast cancer MCF7, T47D and MDAMB-468 cell lines treated with adriamycin. DARU. 2008;16:182–6.
    24. Takemura H, Shim JY, Sayama K, Tsubura A, Zhu BT, Shimoi K. Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J Steroid Biochem Mol Biol. 2007;103(2):170–7. doi: 10.1016/j.jsbmb.2006.08.008. [PubMed: 17097287]
    25. Li Y, Burns KA, Arao Y, Luh CJ, Korach KS. Differential estrogenic actions of endocrine-disrupting chemicals bisphenol A, bisphenol AF, and zearalenone through estrogen receptor alpha and beta in vitro. Environ Health Perspect. 2012;120(7):1029–35. doi: 10.1289/ehp.1104689. [PubMed: 22494775]
    26. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43(1):1–67. doi: 10.1080/10408360500295626. [PubMed: 16531274]
    27. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17β-Estradiol inhibits apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two estrogen-responsive elements present in the coding sequence. Mol Cell Biol . 2000;20(8):2890–901. doi: 10.1128/MCB.20.8.2890- 2901.2000. [PubMed: 10733592] 30. Thomadaki H, Talieri M, Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett. 2007;247(1):48–55. doi: 10.1016/j.canlet.2006.03.016. [PubMed: 16647810]
    28. Eguchi H, Suga K, Saji H, Toi M, Nakachi K, Hayashi SI. Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene. Cell Death Differ. 2000;7(5):439–46. doi: 10.1038/ sj.cdd.4400675. [PubMed: 10800077] 32. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol . 2003;15:158–63. doi: 10.1016/S0955-0674(03)00008-5. [PubMed: 12648671]
    29. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145(12):5439–47. doi: 10.1210/en.2004-0959. [PubMed: 15331580] 34. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996;2(6):923–8. [PubMed: 9816251]
    30. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006;19(7):999–1009. doi: 10.1038/modpathol.3800621. [PubMed: 16648863]
    31. Bilalovic N, Vranic S, Basic H, Tatarevic A, Selak I. Immunohistochemical evaluation of cyclin D1 in breast cancer. Croat Med J. 2005;46(3):382–8. [PubMed: 15861516]
    32. Azizi E, Namazi A, Kaabinejadian S, Fouladdel S, Rezaei P, Ramezani M. Molecular analysis of MEN1 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. Daru. 2010;18(1):17– 22. [PubMed: 22615588]
    33. Lu J, Yu JY, Lim SS, Son YO, Kim DH, Lee SA, et al. Cellular mechanisms of the cytotoxic effects of the zearalenone metabolites alpha-zearalenol and beta-zearalenol on RAW264.7 macrophages. Toxicol In Vitro. 2013;27(3):1007–17. doi: 10.1016/j.tiv.2013.01.011. [PubMed: 23376438]
    34. Khosrokhavar R, Rahimifard N, Shoeibi S, Hamedani MP, Hosseini MJ. Effects of zearalenone and alpha-Zearalenol in comparison with Raloxifene on T47D cells. Toxicol Mech Methods. 2009;19(3):246–50. doi: 10.1080/15376510802455347. [PubMed: 19730705]
    35. Kuciel-Lisieska G, Obremski K, Stelmachow J, Gajecka M, Zielonka L, Jakimiuk E, et al. presence of Zearalenone in blood plasma in women with neoplastic lesions in the mammary gland. Bul Vet Inst Pulawy . 2008;52:671–4.
    36. Ramanathan L, Gray WG. Identification and characterization of a phytoestrogen-specific gene from the MCF-7 human breast cancer cell. Toxicol Appl Pharmacol. 2003;191(2):107–17. [PubMed: 12946647]
    37. Yu Z, Zhang L, Wu D, Liu F. Anti-apoptotic action of zearalenone in MCF-7 cells. Ecotoxicol Environ Saf. 2005;62(3):441–6. doi: 10.1016/j. ecoenv.2004.10.003. [PubMed: 16216639]